NeoStem's stem cell collection abilities highlighted on CBS segment

NeoStem (AMEX:NBS) announced that it was featured on CBS' Eye on New York City program on Wednesday, August 24.
The evening news segment focused on the biopharmaceutical company, which has a special interest in cell-based therapeutics, specifically, on its collection and storage of adult stem cells for first responders, the nuclear industry, the military and the general public.
The company provides healthy adults in the general public the ability to have their stem cells collected and preserved.
Advances in technology have discovered a method for enabling an increased number of stem cells from the body's bone marrow to migrate to the peripheral blood - a process that also happens naturally when there is stress or injury.
The process of retrieving these cells is similar to giving blood. Through the procedure, a candidate's blood is collected, and then is separated from the stem cells, after which the remaining blood cells are immediately deposited back into the body's system.
The entire process takes between three to four hours, after which the stem cells are cryopreserved, or frozen, and can last for decades.
Stem cell treatment is common in cases of acute radiation syndrome, and can also be used to treat several blood cancers, like leukemia.
In cases of fatal radiation exposure, stem cell transplant is one of the only successful treatments available. A transplant completed within seven to ten days of exposure often results in high cure rates. Stem cell transplantation was used in Japan following the Tokaimura nuclear reactor accident in 1999.
"One solution is for people at risk of exposure to prepare by collecting and storing their stem cells before they are exposed, in a safe place until they need them," said CEO, Dr. Robin Smith.
"We are working to align ourselves closely with leaders in the nuclear industry, our military services, and first responders, such as police and firemen, but this is a service that we offer to everyone.
"Since 2000, we have completed over 33,000 cell therapy procedures, stored over 20,000 cell products, and delivered over 6,000 products to be transplanted in patients."